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1. Introduction 
Articular cartilage has a reduced capacity for self-regeneration. Delivery of candidate genes to 
articular chondrocytes is an attractive strategy that has the potential to allow for a durable 
reestablishment of the structural integrity in osteoarthritic (OA) cartilage. Gene transfer 
approaches might be better suited to treat a slow and irreversible disorder such as OA over 
time instead of systems that are based on the application of recombinant factors with relatively 
short pharmacological half-lives. Current approaches that aim at re-equilibrating the metabolic 
balance in OA cartilage are based on the transfer of sequences coding for agents that either 
counteract the processes of matrix degradation or enhance the synthesis of matrix components. 
Importantly for the treatment of OA, the development of effective gene treatments will 
necessitate that the gene vehicle chosen allows for high and also sustained levels of expression 
of the sequence to be delivered due to the slow and irreversible progression of this disorder. 
The method elected to administer the therapeutic composition will be also important to 
achieve successful and long-term cartilage regeneration in OA patients. 
2. Gene therapy 
Gene therapy aims at treating human diseases via gene transfer techniques that introduce 
foreign genes or sequences in various cell types. The foreign material enters the cell where it 
is transferred towards the nucleus. Once there, it either integrates in the host genome or 
stays extrachromosomal under episomal forms that generally allows only for transient 
transgene expression. Gene transfer in sufficient number of cells is essential to allow for the 
production of therapeutically relevant concentrations of transgene products. The currently 
most employed vectors used in gene therapy trials include nonviral compounds (naked 
DNA, physical and chemical methods) and different viral gene carriers including 
adenoviral, herpes simplex virus-derived, retroviral, lentiviral, and recombinant adeno-
associated viral vectors that utilize natural entry pathways in human cells (Cucchiarini et al., 
2009a; Cucchiarini & Madry, 2005; Evans, 2004; Evans et al., 2004) (Table 1). 
2.1 Nonviral vectors 
Chemical methods of complexing DNA to various macromolecules include cationic lipids 
and liposomes, polymers, polyamines and polyethylenimines, and nanoparticles, besides 
the use of calcium phosphate coprecipitates. Nonviral methods avoid the risk of acquiring 
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replication competence inherent to viral vectors. They can be repeatedly administered, have 
the capacity to deliver large therapeutic genes, and are easy to produce on a large scale. 
Also, they do not elicit immune responses in the host organism. Still, their efficacy is often 
much lower than those of viral vectors. In addition, as the transgenes remain as episomes in 
their targets, only short-term transgene expression is achievable. To overcome these 
shortcomings, nonviral gene transfer strategies in vivo are generally based on the use of ex 
vivo-modified cells for readministration in sites of damage. 
 



























































Table 1. Gene Transfer Vectors. 
2.2 Adenoviral vectors 
Adenoviruses have been among the most employed systems so far. They allow for high 
transduction efficiencies and transgene expression in a variety of cells, allowing for direct 
approaches in vivo. Yet, there are serious concerns about their safe use in the clinics due to 
the development of strong host immune responses to the remaining adenoviral gene 
products. Another problem is the limited period of transgene expression (1-2 weeks) as the 
sequences delivered remain as episomes that are cleared shortly after being introduced in 
the cells. 
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2.3 Retroviral vectors 
An advantage of these viruses is their ability to integrate in the host genome, allowing for 
the maintenance of the transgene over extended periods of time. Nevertheless, this might 
lead to insertional mutagenesis and a potential to activate tumorigenic sequences. Also, such 
vectors transduce only dividing cells with a restricted host range (and a low efficacy) and 
are only produce at relatively low concentrations. Therefore, ex vivo approaches with pre-
selection of transduced cells are usually employed. Interestingly, lentiviral vectors, a 
subclass of retroviruses derived from the human immunodeficiency virus (HIV) that 
integrate in the genome of nondividing cells avoid the need for cell division and show 
higher levels of transduction in vivo. Nevertheless, there are still concerns associated with 
their application, including the potential for insertional mutagenesis and the psychological 
problem of introducing genetic material carrying HIV sequences. 
2.4 Herpes simplex viral vectors (HSV) 
HSV-derived vectors are large vehicles that can deliver large transgenes to almost all known 
cell types, including nondividing cells. Although first-generation vectors induced high 
levels of cytoxicity, recent work has demonstrated that second-generation HSV were less 
deleterious, in particular for cartilage gene transfer. One problem remains the transient 
nature of transgene expression mediated by this family of vectors. 
2.5 Recombinant adeno-associated viral vectors (rAAV) 
Application of viral vectors raises additional safety concerns, as potentially infectious 
agents or sequences might be introduced per se in the body. This is particularly important 
for the treatment of OA as it is not a life-threatening disorder. In this regard, rAAV 
vectors based on the nonpathogenic, replication-defective human parvovirus AAV might 
be more adequate for gene therapy settings. rAAV are produced by complete removal of 
the viral gene coding sequences, making them less immunogenic than adenoviral vectors 
and less toxic than HSV. Also, rAAV can be transcribed in their targets at very high 
efficiencies for months to years due to the stabilization of the episomal transgene cassettes 
by concatemer formation, making them strong alternatives for direct gene transfer 
approaches in vivo. Cell division and integration are not required for expression of the 
foreign material delivered via rAAV, in marked contrast with retroviral vectors. Redosing 
of vectors is practicable with rAAV, based on the use of various serotypes of the virus. For 
these reasons, rAAV became a preferred gene transfer method for experimental settings in 
vivo and for clinical applications. 
3. Osteoarthritis 
3.1 Articular cartilage 
Adult hyaline articular cartilage is an avascular and aneural tissue that does not possess a 
lymphatic drainage that allows for a smooth gliding of the articulating surfaces of a joint 
and protects the subchondral bone from mechanical stress. Hyaline articular cartilage has 
several laminar zones formed by chondrocytes surrounded by an intricate network of 
extracellular matrix rich in proteoglycans and collagen fibrils (mostly type-II collagen and 
also types type-VI, -IX, -XI, and -XIV collagens and additional macromolecules). Normal 
hyaline articular cartilage contains about 70-80% water bound to proteoglycans. The 
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chondrocytes regulate the structural and functional properties of the cartilage according to 
the applied loads by producing and degrading the extracellular matrix. 
3.2 Osteoarthritis 
Osteoarthritis (OA) is the most disabling condition and prevalent form of arthritis (80%). 
OA is a chronic disorder of diarthrodial joints, mainly characterized by a slow, progressive, 
and irreversible deterioration of the articular cartilage, with changes in the subchondral 
bone. OA also affects to a minor degree the synovial lining, ligaments, tendons, and 
muscles. 
OA is a complex disorder characterized by the activation of inflammatory cascades and 
alterations of the chondrocyte phenotype, leading ultimately to cartilage breakdown (loss of 
the major components of the cartilage matrix). Under mechanical or biochemical stress 
(interleukin-1, i.e. IL-1; tumor necrosis factor alpha, i.e. TNF-┙; nitric oxide, i.e. NO, 
prostaglandins, matrix degradation products), the cells undergo pathological changes in 
gene expression patterns that impede the whole homeostasis: diminished production of 
matrix molecules, enhanced production of matrix-degrading enzymes (matrix 
metalloproteinases, i.e. MMPs; adamalysins), decreased responsiveness to reparative 
stimuli, degradation of the matrix, alteration of the cell viability, cell senescence with 
apoptosis (NO; Fas/FasL signaling). 
Several nonsurgical options are available to manage the progression of OA, including 
pharmacological treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), slow-
acting drugs in OA (SADOAs) like glucosamine, chondroitin sulfate, and diacerin, being 
either symptomatic slow-acting drugs in OA (SYSADOAs) or disease-modifying OA drugs 
(DMOADs). However, there is no convincing evidence yet that such drugs indeed modify or 
inhibit the progression of OA. Surgical interventions such as débridement, marrow 
stimulation, and osteotomy are specifically indicated in early stages of OA. Yet, restoration 
of a native cartilage that is identical in its structure to the normal cartilage and capable of 
withstanding mechanical stresses over time in OA has not been achieved to date. Causative 
treatment for OA therefore remains a problem, particularly troublesome for patients that are 
too young to undergo endoprosthetic joint replacement. 
4. Osteoarthritis gene therapy 
4.1 Target cells in OA – Gene transfer in vitro 
Target cells in the OA joint include: 
1. chondrocytes, 
2. osteocytes, 
3. cells of the synovial lining, 
4. progenitor cells, or 
5. cells of surrounding tissues (muscle, tendons, ligaments, meniscus). 
Application of nonviral (Gerich et al., 1997b; Grossin et al., 2006; Kaul et al., 2006; Madry 
et al., 2004b; Madry et al., 2005; Madry et al., 2001; Nita et al., 1996; Tsuchiya et al., 2003; 
Zhang, H. N. et al., 2009), adenoviral (Baragi et al., 1995; Brower-Toland et al., 2001; Gelse 
et al., 2001; Gerich et al., 1997a; Gerich et al., 1996; Gerich et al., 1997b; Goto et al., 1999; 
Haupt et al., 2005; Ikeda et al., 2004; Li et al., 2004; Lou et al., 1997; Mehrara et al., 1999; 
Musgrave et al., 2002; Nita et al., 1996; Nixon et al., 2000; Nixon et al., 2005; Saxer et al., 
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 2001; Shuler et al., 2000; Smith et al., 2000; Steinert et al., 2007; Steinert et al., 2009; 
Steinert et al., 2008), or retroviral vectors (Baltzer et al., 1999; Gerich et al., 1997a; Gerich et 
al., 1996; Gerich et al., 1997b; Goto et al., 2000; Gouze, J. N. et al., 2003; Hildebrand et al., 
1999; Li et al., 2004; Mason et al., 2000; Nita et al., 1996; Piera-Velazquez et al., 2002; 
Roessler et al., 1995; Tew et al., 2005) has been achieved in such cells with more or less 
success. rAAV are potent alternatives as they efficiently and durably transduce 
synoviocytes (Adriaansen et al., 2007; Apparailly et al., 2002; Goater et al., 2000; Goodrich 
et al., 2009; Hiraide et al., 2005; Traister et al., 2006; Zhang, H. G. et al., 2000), 
chondrocytes (Arai et al., 2000; Cucchiarini et al., 2005; Cucchiarini et al., 2009c; 
Cucchiarini et al., 2007; Dai & Rabie, 2007; Goodrich et al., 2009; Madry et al., 2003; Ulrich-
Vinther et al., 2002; Ulrich-Vinther et al., 2005; Yokoo et al., 2005), mesenchymal stem cells 
(MSCs) (Chamberlain et al., 2008; Chamberlain et al., 2004; Chen, M. et al., 2011; 
Cucchiarini et al., 2011; Cucchiarini et al., 2005; Dai & Rabie, 2007; Ito et al., 2004; Kim, S. 
J. et al., 2007; Pagnotto et al., 2007; Shi & Wang, 2010; Stender et al., 2007), and other cell 
types relevant of the pathogenesis of OA (Arsic et al., 2004; Basile et al., 2008; Cucchiarini 
et al., 2009b; Gerich et al., 1997a; Gerich et al., 1997b; Ito et al., 2005; Kessler et al., 1996; 
Luk et al., 2003; Madry et al., 2004a; Tang et al., 2008; Wang et al., 2007; Wang et al., 2005). 
Regeneration of a native (structural and functional) cartilage architecture might be achieved 
by: 
1. inhibiting inflammatory and catabolic pathways, 
2. stimulating anabolic pathways to rebuild the matrix, 
3. impeding cell senescence, 
4. avoiding the pathological formation of osteophytes, 
5. prevention of apoptosis, and/or 
6. influencing several of these processes. 
Inhibition of catabolic pathways has been observed when expressing inhibitors of matrix-
degrading enzymes (tissue inhibitor of MMPs, i.e. TIMP) (Kafienah et al., 2003), inhibitors of 
proinflammatory cytokines (IL-1Ra; the soluble receptors sIL-1R or sTNFR) (Attur et al., 
2002; Baragi et al., 1995; Gouze, J. N. et al., 2003; Haupt et al., 2005; Roessler et al., 1995; 
Zhang, H. G. et al., 2000; Zhang, X. et al., 2006), and chondroprotective cytokines (IL-4; IL-
10) (Kim, S. H. et al., 2001; Zhang, X. et al., 2006). Activation of anabolic processes has been 
noted by single or combined administration of components of the cartilage matrix or of the 
enzymes that synthesize them (Dharmavaram et al., 1999; Venkatesan et al., 2004), of growth 
factors and receptors (insulin-like growth factor I, i.e. IGF-I; fibroblast growth factor 2, i.e. 
FGF-2; bone morphogenetic proteins, i.e. BMPs; transforming growth factor beta, i.e. TGF-┚) 
(Brower-Toland et al., 2001; Chen, B. et al., 2010; Cucchiarini et al., 2011; Cucchiarini et al., 
2005; Cucchiarini et al., 2009c; Haupt et al., 2005; Lee et al., 2005; Madry et al., 2004b; Madry 
et al., 2001; Nixon et al., 2000; Nixon et al., 2005; Saxer et al., 2001; Schmal et al., 2005; Shuler 
et al., 2000; Smith et al., 2000; Ulrich-Vinther et al., 2005), and of transcription factors (SOX 
family of DNA-binding proteins, i.e. SOX5, SOX6, SOX9) (Cucchiarini et al., 2007; Ikeda et 
al., 2004; Li et al., 2004; Tew et al., 2005; Tsuchiya et al., 2003). Restoration of cell vitality and 
activation of proliferation have been achieved by application of IGF-I or FGF-2 (Cucchiarini 
et al., 2011; Cucchiarini et al., 2005; Cucchiarini et al., 2009c; Kaul et al., 2006; Madry et al., 
2004b; Madry et al., 2001; Schmal et al., 2005), telomerase (hTERT) (Piera-Velazquez et al., 
2002), of inhibitors of apoptosis (bcl-2) (Surendran et al., 2006), or of the heat shock protein 
70 (HSP70) (Grossin et al., 2006). Remarkably, approaches that influence several of these 
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processes have been also successfully attempted, like combining the transfer of inhibitors of 
catabolism pathways and of activators of anabolic events (IGF-I/IL-1Ra) (Haupt et al., 2005; 
Nixon et al., 2005), as well as that of activators of anabolic and proliferative processes (FGF-
2/SOX9 or FGF-2/IGF-I) (Cucchiarini et al., 2009c; Orth et al., 2011). 
4.2 Gene transfer in vivo 
4.2.1 Direct gene transfer 
The key issue in establishing an efficient therapy against OA is to access the targets of the 
treatment when the cells reside in the joint cavity. The following approaches have been 
therefore developed: 
1. systemic delivery and 
2. intraarticular administration: 
2.1 by injection or 
2.2 using arthrotomy 
Systemic approaches are better suited to target diseases that are systemic in nature like 
rheumatoid arthritis (RA) (Evans et al., 2006b, 2009; Jorgensen & Apparailly, 2010). 
Local administration of components might be preferable for OA that affects only a limited 
number of joints without major systemic manifestations. Intraarticular injection of most 
vector types preferentially transduce the synovium (Ghivizzani et al., 1997; Gouze, E. et al., 
2002; Nita et al., 1996; Roessler et al., 1993), being rather suited for strategies aiming at 
inhibiting inflammatory and catabolic pathways (and a common approach employed 
against experimental RA). Direct application of gene vectors has been attempted in 
experimental OA using sequences coding for IL-1Ra (Fernandes et al., 1999; Frisbie et al., 
2002; Frisbie & McIlwraith, 2000; Zhang, X. et al., 2006), IL-10 (Zhang, X. et al., 2006), HSP70 
(Grossin et al., 2006), gene silencers (Chen, L. X. et al., 2008), or kallistatin and 
thrombospondin-1 (Hsieh et al., 2009; Hsieh et al., 2010). Yet, even if cartilage breakdown is 
contained, this may not be sufficient to fully compensate for the loss of matrix elements and 
cells noted during the disease progression. In this regard, synthesis of cartilage matrix 
components might be stimulated by providing vectors carrying genes for anabolic factors 
(FGF-2, IGF-I) (Chen, B. et al., 2010). 
4.2.2 Indirect gene transfer 
Ex vivo gene therapy is more complex but safer as no free vector particles are introduced in 
the body. Also, modified cells can be controlled, tested, and selected in culture. 
Administration of cells is also a means to increase the cellularity like needed for cases of 
severe OA. 
Synoviocytes have been mostly employed to deliver inhibitors of inflammatory and 
catabolic processes (Pelletier et al., 1997; Zhang, X. et al., 2004). Such pathways were 
regulated by injecting cells overexpressing an IL-1Ra alone (Pelletier et al., 1997; Zhang, X. et 
al., 2004) or with IL-10 (Zhang, X. et al., 2004). Again, although OA was reduced in 
association with decreased cartilage breakdown, complete resurfacing was not reported. 
Nevertheless, the use of differentiated cells is impaired by the invasive methods of 
preparation from unaffected sites with a limited supply and by common changes in cell 
phenotype observed upon passaging in culture. Also, implantation of committed cells 
generally leads to the formation of a poorly differentiated (fibrous) cartilage. Progenitor cells 
might be better suited to generate a cartilage of enhanced quality in transplantation settings. 
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They can be easily isolated from multiple tissues (bone marrow, periosteum, 
perichondrium, muscle, fat, subdermis, cartilage, bone, synovial membrane, ligaments), 
even in OA patients, maintaining a multilineage potential with a reliability for 
differentiation and a capacity for expansion (Barry & Murphy, 2004; Yoo et al., 2000). 
Remarkably, injection of muscle-derived stem cells modified by combined gene transfer of 
BMP-4 with sFlt1 (an antagonist of the vascular endothelial growth factor, i.e. VEGF) 
allowed for cartilage repair in a rat model of OA (Matsumoto et al., 2009). 
5. Clinical trials 
Preclinical data, as those described above, have encouraged the initiation of human clinical 
trials mostly for RA. The first studies were based on retroviral gene transfer of human IL-
1Ra in synoviocytes from RA patients and reinjection in the metacarpophalangeal joint 
(Evans et al., 2000a; Evans et al., 1996; Wehling et al., 2009). Transgene expression was noted 
locally without adverse events, leading to clinical improvements in some patients, 
encouraging the implementation of phase II studies (Evans, 2005; Evans et al., 2005a; Evans 
et al., 2000b; Evans et al., 2006a, 2008; Evans et al., 2004; Evans et al., 2005b; Robbins et al., 
2003). Direct intraarticular injection of rAAV carrying an sTNFR-immunoglobulin in RA 
patients revealed that the treatment was safe and well tolerated (Evans, 2005; Evans et al., 
2005a; Evans et al., 2006a, 2008; Mease et al., 2009), and a phase I/II trial was subsequently 
started. Regarding OA, a phase I protocol is ongoing, based on an ex vivo approach using the 
retroviral transfer of TGF-┚ (Evans et al., 2008). 
6. Conclusions 
Gene therapy holds great promise, but issues that need to be addressed include the duration 
of transgene expression, extended analyses in clinically relevant animal models, the benefit 
of ex vivo genetically modified cells versus direct approaches, and the identification of 
optimal therapeutic factors. Future studies will also have to shed light on the safety of these 
approaches regarding the nonlethal nature of OA. Successful application of gene therapy for 
OA requires a combined effort of surgeons and basic scientists in order to improve the 
currently available gene transfer systems. 
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